Rapid Test Kit Patent Landscape Report 2026 Edition

The global rapid test kit market was valued at USD 46.99 Billion in 2025. The market is anticipated to grow at a CAGR of 9.10% during the forecast period of 2026-2035, with the values likely to reach USD 112.27 Billion by 2035. The market growth is driven by the increasing demand for point-of-care (POC) diagnostics. Patents are focused on advanced technologies such as PCR, immunoassay, and HPLC, among others.

Patent Landscape Report Coverage

The Global Rapid Test Kit Patent Landscape Report provides a comprehensive and in-depth analysis of the patents in this growing industry. The key sections captured in the report for rapid test kit include a thorough examination of the patent portfolios of key players, covering aspects such as the number of patents and types of technologies patented. It includes the latest trends, geographical distribution of patents, top IP player profiles, technological segmentation, and patent valuation associated with rapid test kits. The breakdown of patents by technical segments is provided, giving more clarity on the specific areas of innovation within rapid test kit technologies.

Key Inclusions:

• Patent Valuation Analysis

An evaluation and competitive benchmarking of key members of unique patent families are covered in the analysis for rapid test kit technologies. The important parameters have been taken into consideration including IP document, year of application, number of citations, time to expiry, and jurisdiction associated with the rapid test kit.

• Analysis of Patent Applications

A comprehensive summary of several patent applications which were filed across different jurisdictions for rapid test kits and their relative value are covered. The analysis will cover the capital in terms of innovation and innovation type.

• Analysis of Granted Patents

Detailed analysis of the granted patents across different jurisdictions for rapid test kits and their relative value in the IP are covered in the final report.

What are Rapid Test Kits?

Rapid test kits are point-of-care diagnostic instruments made to provide precise and timely results in a matter of minutes without requiring processing in a lab. These kits identify illnesses, infections, or biomarkers in blood, urine, saliva, or swab samples using lateral flow, immunoassay, or molecular detection techniques. In both clinical and home settings, they are frequently utilized for chronic disease monitoring, pregnancy testing, and the detection of infectious diseases (such as COVID-19, HIV, and malaria).

The components of rapid test kits include rapid antigen and rapid antibody. Rapid antigen test kits are point-of-care diagnostic instruments made to identify viral antigens in a sample, usually taken with a throat or nasal swab. These kits are popular for identifying respiratory infections like influenza and COVID-19 because they yield results quickly (within 15 to 30 minutes). Although their sensitivity may be lower than that of molecular tests like PCR, they are inexpensive, simple to use, and appropriate for mass screening.

Rapid Test Kit Industry Growth Drivers

Technological Advancements in Speed and Test Accuracy is Expected to Boost the Patent Industry Growth

Rapid test kits are becoming faster and more precise due to the technological advancements in test platforms. For instance, Abbott Laboratories was granted a patent for their ID NOW COVID-19 rapid antigen test in 2020. It uses molecular amplification technology to deliver results in as little as 15 minutes. This development pushed the market for quick molecular tests forward by greatly increasing the test's sensitivity and detection speed.

There is an increase in patent activity which focuses on enhancing the performance of rapid test kits. In 2023, 9,658 patents were granted which increased to 10,403 by 2024. Patents covering these technologies are crucial for companies and thus impact the rapid test kit patent landscape.

Increasing Demand for Point-of-Care Testing is Expected to Propel Rapid Test Kit Patent Industry

One of the main factors propelling the market for rapid test kits is the growing demand for point-of-care (POC) diagnostics. These tests provide prompt, convenient, and on-site results, particularly in emergency and remote situations, which minimizes the need for laboratory visits and permits prompt clinical decisions.

Rapid Test Kit Patent Segmentation

The report will cover the following sections in detail:

Analysis by Type

• Rapid Antigen
• Rapid Antibody

Analysis by Mode of Purchase

• Over-The-Counter Rapid Test Products
• Professional Rapid Test Products

Analysis by Technology

• PCR
• Immunoassay
• HPLC
• Others

Rapid Test Kit Patent Segmentation Analysis

The breakup based on the mode of purchase includes over-the-counter rapid test products and professional rapid test products. Consumers can obtain self-use diagnostic kits known as over-the-counter (OTC) rapid test products without a prescription. These tests, which are frequently used to detect HIV, COVID-19, and pregnancy, are easy to use at home and offer fast results (usually in 15 to 30 minutes). They are frequently used for early detection and provide an affordable, convenient means of keeping an eye on medical conditions without having to go to a hospital.

Rapid Test Kit Patent Jurisdiction Analysis

The United States is one of the leading jurisdictions for rapid test kit patents, having around 396,000+ patents. The presence of big companies, well-established healthcare infrastructure, and advanced research and development activities contributes to the regional patent landscape significantly.

Patent Profile of Key Companies

Among the players with rapid test kit patent families, new entrants have been identified, which can be either established companies or startups developing their first technology in the rapid test kit field. Some of the major companies mentioned in this report (a non-exhaustive list) are as follows:

Becton Dickinson Co.

Global medical technology company Becton, Dickinson and Company (BD) specializes in biosciences, diagnostics, and medical devices, such as quick test kits for COVID-19, the flu, and infectious diseases. It was established in 1897 and is based in Franklin Lakes, New Jersey, in the United States. Rapid diagnostic solutions from BD improve disease detection and management while also enhancing point-of-care testing.

Brahms Gmbh

B·R·A·H·M·S GmbH is a biotechnology company that specializes in rapid test kits and in-vitro diagnostics, especially for bacterial infections, hormone disorders, and sepsis. B·R·A·H·M·S GmbH was established in 1994 and is a subsidiary of Thermo Fisher Scientific. Its headquarters are in Hennigsdorf, Germany. The business is well-known for its rapid procalcitonin (PCT) tests, which are frequently used in infectious disease and critical care diagnostics.

Other companies are Jordanian Pharmaceutical Mfg, Biolytical Laboratories Inc., and Eachy Biopharmaceuticals Co. Ltd, among others.

Reasons to Purchase this Report

The rapid test kit patent report provides information on the intellectual property (IP) position and strategy of key players. This report can help companies and players looking to enter or invest in this field by:

• Competitive Advantage: The landscape reveals the market leaders, potential partners and innovators and makes it understandable which companies have important patents in this field of rapid test kits.
• Innovation Insights: The patent analysis reveals new innovations and technologies in rapid test kits.
• Market Positioning: Companies with strong patent portfolios gain a competitive advantage because their intellectual property assets differentiate their products. Understanding their intellectual property strategy reveals the market position of new entrants and potential barriers to entry within the rapid test kits patent landscape.
• Risk Assessment: In technology-intensive fields such as rapid test kits, risks of IP infringement are common. Analyzing patent landscapes helps companies assess risk, develop mitigation strategies, and inform licensing, partnering, and acquisition decisions.

Key Questions Answered in the Rapid Test Kit Patent Landscape Report

• Who are the key players in the rapid test kit patent landscape?
• How is the patent portfolio distributed geographically?
• What are the emerging trends in rapid test kit patents?
• How has the patent landscape evolved over time?
• What are the strategic insights for market players and investors?
• What is the technological focus of patents in the rapid test kit industry?
• How do patent strategies impact competitive advantage?
• What are the implications of patent filings in rapid test kits?
• What are the challenges and opportunities in the rapid test kit patent landscape?
• What are the regulatory and legal considerations?
• What technological innovations have recently emerged in rapid test kits?